表紙
市場調查報告書

心律不整治療藥的全球市場:2019年∼2023年

Global Cardiac Arrhythmias Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 900601
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
心律不整治療藥的全球市場:2019年∼2023年 Global Cardiac Arrhythmias Therapeutics Market 2019-2023
出版日期: 2019年07月29日內容資訊: 英文 130 Pages
簡介

全球心律不整治療藥市場,2018年,口服心律不整治療藥的低成本、可用性、無痛、徐放效果等成為要素,口服藥市場區隔獲得很大的市場佔有率,預計這個趨勢在預測期間也將持續。還有該市場,預計血栓症的盛行率增加,正確的診斷方法的利用可能性,心血管疾病相關意識的高漲等成為成長促進因素,在預測期間內預計將以4%以上的年複合成長率擴大。但,心律不整治療藥相關的黑盒警示,替代產品的可得性,嚴格的法規環境,可能妨礙在預測期間內心律不整治療藥產業的成長。

本報告提供全球心律不整治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2018年∼2023年)
  • 口服藥
  • 靜脈注射
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 控制AF的心律的基因治療的登場
  • 可早期發現心律不整的技術進步
  • 供應商的研究開發努力的發展

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31782

About this market

Cardiac arrhythmias therapeutics are pharmaceutical agents that are used to normalize the issue of cardiac arrhythmia. Technavio's cardiac arrhythmias therapeutics market analysis considers sales from both oral and intravenous applications. Our analysis also considers the sales of cardiac arrhythmias therapeutics in North America, Europe, Asia and the rest of the world (ROW). In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as Low cost, easy to consume, no pain, extended-release effect of oral arrhythmias therapeutics will play a significant role in the oral segment to maintain its market position. Also, our global cardiac arrhythmias therapeutics market report also looks at factors such as the growing prevalence of thrombosis, availability of precise diagnostic methods, rising awareness about cardiovascular diseases. However, black box warning associated with cardiac arrhythmias therapeutics, availability of substitute products, stringent regulatory environment may hamper the growth of the cardiac arrhythmias therapeutics industry over the forecast period.

Overview

Availability of precise diagnostic methods

The availability of precise diagnostic methods, like electrocardiogram (ECG) Hotter monitors, event monitors, stress IQ tests, echocardiogram, cardiac catheterization, electrophysiology study (EPS), and head-up tiff table tests have led to increase in the diagnosis rate of cardiac arrhythmias, thus contributing to increased prescription of therapeutics for cardiac arrhythmias. Such factors will lead to the expansion of the global cardiac arrhythmias therapeutics market at a CAGR of over 4% during the forecast period.

The advent of gene therapy to control ventricular rate in AF

The current treatment therapy for AF involves the use of antiarrhythmic drugs to sustain the sinus rhythm or drugs that can curb the conduction in the atrioventricular (AV) node in order to control the ventricular rate. The medication therapy used for the treatment of arrhythmia exerts its pharmacological effect by targeting the conduction properties of the AV node- by suppressing the calcium current or by altering the cholinergic and adrenergic tone. Therefore, the global cardiac arrhythmias therapeutics market presents an urgent need for the development of biological drugs, which can target the gene and thus, improve cardiac functioning. Ongoing research in this area is expected to have a positive impact on market growth during the forecast period.

For the detailed list of factors that will drive the global cardiac arrhythmias therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global cardiac arrhythmias therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiac arrhythmias therapeutics manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the cardiac arrhythmias therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Intravenous - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • The advent of gene therapy to control ventricular rate in AF
  • Technological advances enabling the early detection of cardiac arrhythmias
  • Growing R&D efforts by vendors

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Application - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Intravenous - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Intravenous - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by application
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Diagnostic methods
  • Exhibit 43: Side-effects of cardiac arrhythmias therapeutics
  • Exhibit 44: Substitute products to cardiac arrhythmias therapeutics
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bayer AG - Vendor overview
  • Exhibit 52: Bayer AG - Business segments
  • Exhibit 53: Bayer AG - Organizational developments
  • Exhibit 54: Bayer AG - Geographic focus
  • Exhibit 55: Bayer AG - Segment focus
  • Exhibit 56: Bayer AG - Key offerings
  • Exhibit 57: Bayer AG - Key customers
  • Exhibit 58: Eli Lilly and Co. - Vendor overview
  • Exhibit 59: Eli Lilly and Co. - Business segments
  • Exhibit 60: Eli Lilly and Co. - Organizational developments
  • Exhibit 61: Eli Lilly and Co. - Geographic focus
  • Exhibit 62: Eli Lilly and Co. - Segment focus
  • Exhibit 63: Eli Lilly and Co. - Key offerings
  • Exhibit 64: Eli Lilly and Co. - Key customers
  • Exhibit 65: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 66: GlaxoSmithKline Plc - Business segments
  • Exhibit 67: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 68: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 69: GlaxoSmithKline Plc - Segment focus
  • Exhibit 70: GlaxoSmithKline Plc - Key offerings
  • Exhibit 71: GlaxoSmithKline Plc - Key customers
  • Exhibit 72: Pfizer Inc. - Vendor overview
  • Exhibit 73: Pfizer Inc. - Business segments
  • Exhibit 74: Pfizer Inc. - Organizational developments
  • Exhibit 75: Pfizer Inc. - Geographic focus
  • Exhibit 76: Pfizer Inc. - Segment focus
  • Exhibit 77: Pfizer Inc. - Key offerings
  • Exhibit 78: Pfizer Inc. - Key customers
  • Exhibit 79: Sanofi - Vendor overview
  • Exhibit 80: Sanofi - Business segments
  • Exhibit 81: Sanofi - Organizational developments
  • Exhibit 82: Sanofi - Geographic focus
  • Exhibit 83: Sanofi - Segment focus
  • Exhibit 84: Sanofi - Key offerings
  • Exhibit 85: Sanofi - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top